Know the FDA Process: Key to Biotech Investment Success
Investors should understand the #FDA regulatory process well. Here is a quick summary At each step investors should ask themselves if the company is developing things in a way that will satisfy the FDA Until a drug is approved the FDA is the most important decision maker #BiotechPrometheus
Independent Low-Cost Vaccines Keep Pfizer Out of Markets
ANS: I don’t take a dime from Pfizer or any other big pharma company. If and when you decide to visit a library instead of relying on conspiracy sites, you’ll find we develop low cost, patent free vaccines that bypass...
JPM Acts as Audit, Reveals Biotech Translation Friction
JPM Isn’t a Conference. It’s an Audit. What 1,000 companies and 6 years of data quietly tell you about biotech translation. Part 1. Why you should care. JPM decides who looks fundable before a single new dataset drops. That sounds backward, but it...
Investors Now Require Clean Data and Clear Milestones
From Proof to Payoff | Ep. 900 2025 changed biotech translation. Capital came back with rules. No data, no money. Clean data, financing opens. If your next readout doesn’t force a decision, you stall, no matter how pretty the biology looks. What the market pays for...
Zanidatamab Plus Tislelizumab Raises Diarrhea Risk
#GI26 zanidatamab/chemo ± tislelizumab in the HERIZON-GEA-01 trial: not much attention on side effect profile. If you combine zani, tisle and 5FU you will get more diarrhea/discontinuations https://t.co/55aDi7Pnpx
Merck in Talks to Acquire Revolution Medicines, Deal Uncertain
Our man @mroliverbarnes $MRK $RVMD https://t.co/vUssAaRo5e US pharmaceutical group Merck is in talks to buy Revolution Medicines, a cancer drugmaker with a market capitalisation of nearly $19bn, in what would be the latest big deal in the red-hot biotechnology...
Multi-Omic Atlas Shows Women’s Stronger Immunity, Age‑Related Decline
We're learning more about our immune system from a new, comprehensive, multi-omic atlas in @ScienceMagazine today, such as the stronger immune system in women and the age-related features of immunosenescence https://t.co/4B85BwohBb https://t.co/DHNIUKcQmE
AlphaFold Sparks Surge in Genome-Wide Drug Discovery
In the post-AlphaFold era, drug discovery is on a tear —Genome-wide virtual screening @ScienceMagazine https://t.co/GPyjSK6PcM —Transforming the industry in many ways @TheEconomist https://t.co/ppAMkbFqMp
Lilly Tests Zepbound to Drive Taltz Sales
$LLY runs a psoriatic arthritis marketing study of Zepbound hoping to boost sales of Taltz. @elaineywchen sees right through it. Eli Lilly’s Zepbound, on top of immunology drug, helped reduce psoriatic arthritis symptoms https://t.co/pcmEhIZgWY
Rampart's Fall Highlights Struggles in Legacy Gene Therapy
Ryan's story notes that it's hard to tell exactly what killed Rampart. The faltering gene therapy field, specific scientific challenges, (any internal conflict). Maybe all of the above? No matter what, though, another sign of the cold wind blowing through...
AI-Driven Tracking of Tumor Evolution Reshapes Cancer Therapy
The plan to revolutionize cancer treatment by tracking and responding to evolution of tumor, emergence of resistance, and multimodal AI https://t.co/9PhOrtkiBM @Cancer_Cell @ARPA_H
Cellular Reprogramming Paves Path to Anti‑Aging Organs
Anti-aging and organ rejuvenation strategies, a review https://t.co/ZycCqjZwKk @CellStemCell Figure summary of cellular reprogramming efforts https://t.co/YKgGKukuYb
Treg Breakthroughs: Nobel‑winning Science Moves Toward Clinics
The science of regulatory T cells (Tregs) got the @NobelPrize last year. Now a first-rate review of where they are headed in the clinical arena https://t.co/4xjNAeG3MV https://t.co/MZCDyBc4jq
FDA's Prasad Paradox: Conflicting Strictness on Bespoke Therapies
Predictions for cell therapy and gene therapy in 2026. Most interesting is the "Prasad Paradox", meaning a general state of contradiction at the FDA biologics division around laxness and strictness, including misapplication of the concept of "bespoke" therapies.
Cloning Error Deletes Lac Operator and T5 Promoter
Man, not my lucky day with cloning. A positive control plasmid had one of its lac operators and the -10 element of the T5 promoter removed during cloning. Gonna screen a few more. https://t.co/O09jf6Qf7F
Parabilis Secures $305M, CEO Signals IPO Plans
Mathai on quarterly conference calls? Parabilis Medicines raises $305 million as CEO warms to an IPO By @ADeAngelis_bio https://t.co/h6I9BXDuLS via @statnews
Ocular Therapeutix's Durable Eye Therapy Faces Upcoming Test
This week's Biotech Scorecard newsletter: Ocular Therapeutix $OCUL faces looming test of a more durable eye treatment. A preview of the Axpaxli SOL-1 clinical trial readout expected in February https://t.co/XTI2wySnbB
Dataset in Hg19 Forces Costly Remapping to Hg38
1/ Found the perfect ChIP-seq dataset on GEO. Then saw "hg19" in the methods. Now you need to remap everything to hg38 before you can integrate it with your data. And the authors didn't share their processing pipeline. https://t.co/3Ui4dyEnkb
Low‑dose IL‑2 Curbs Artery Inflammation, Boosts Tregs
Blocking artery inflammation and increasing Treg cells in a small randomized trial with low-dose interleukin-2 https://t.co/ecEEnwUuhr
Jonathan Norris' Venture Healthcare Report: Must‑Read, Download Now
Every year at this time, Jonathan Norris' Venture Healthcare Report is a can't miss. It's out now. Download at the link below.👇
Bioinformatics Evolves Fast—Static Recipes Become Outdated
1/ Bioinformatics moves fast. If you rely only on recipes from books, you’ll soon find they’re obsolete. Let me show you why. 🧵 https://t.co/aYztybAnOu
Why JPM2026 Is the Must‑Watch BioTech Event
As we are heading into the most important week in the BioTech & Pharma sector - #JPM2026 - here is an excellent 🧵👇by @statnews’ @adamfeuerstein which explains - to those less familiar, what is exactly #JPM26 & why it is...
Autoclaving Phosphate with Agar Kills Bacterial Colonies
Got no colonies? Maybe you autoclaved the phosphate and agar at the same time. One more thing to panic about. https://t.co/HtnrMLFdml
Advancing Rare Disease Therapies: Policy and Regulatory Outlook
I’m coming up on @SquawkCNBC where I’ll be discussing recent advances in the treatment of rare diseases and the policy and regulatory path for bringing them to patients. https://t.co/9xsIvvY5Tm
2026 Marks First AI Prescription Renewals and ChatGPT Health
2026 is off with two new precedents in health and medical AI —@doctronic given green light in Utah for AI prescription renewals, pilot study 250 patients https://t.co/EQ3fmqWwyz —ChatGPT Health initiated https://t.co/VOvd3wVkeR @fidjissimo Both need prospective study, rigorous independent assessment, and report of results
Trust Library Sources over Conspiracy for Vaccine Facts
Our friend needs to visit the public library, and rely less on conspiracy sites. I develop low cost vaccines for the world’s poorest people, which actually bypass big pharma. Almost all childhood vaccines are tested through RCTs, available National Library...
Timing Pays: Ventyx Deal Rewards Early IPO Investors
Ventyx $VTYX acquired by Lilly $LLY for $14/share or $1.2B valuation. IPO'd in 2021 at $16/share, around $800M market cap. So acquisition is like ~15% below the IPO price but ~50% above the IPO valuation Great pivot from TYK2 lead program...
GISAID Faces New Issues Compromising Viral Sequence Data
Repeating to fix link: More problems with #GISAID, the international database that is the key repository of #flu and #Covid viral sequences, @kakape reports. https://t.co/YCblC7jSpf
ABVX's UC Expansion Will Boost M&A Valuation
Prediction: High penetration of the existing UC market is one thing, but $ABVX expanding the UC market on their own will be looked back on as the key piece that ultimately took the M&A value to the next...
AI Predicts Hundreds of Diseases Years Ahead From Health Data
Large health models and predicting diseases —In September, >1,200 diseases predicted and when, by EHR and lifestyle factors, for 20-years forward https://t.co/31prJJL1v6 —Yesterday, >130 diseases were predicted from 1 night of sleep data and EHR (Figure) https://t.co/ebHlmaWjfK
AbbVie’s $20B RVMD Acquisition Hits JPM26 M&A Milestone
$ABBV taking out $RVMD would certainly check the #JPM26 big M&A box. $20B plus deal.
Autonomous Brain Microchips Eliminate Need for Surgery
Excited to share the recent #Forbes article featuring our technology, #Circulatronics — a new generation of 𝐛𝐫𝐚𝐢𝐧 𝐦𝐢𝐜𝐫𝐨𝐜𝐡𝐢𝐩𝐬 that are 𝐚𝐮𝐭𝐨𝐧𝐨𝐦𝐨𝐮𝐬 𝐚𝐧𝐝 𝐬𝐮𝐫𝐠𝐞𝐫𝐲-𝐟𝐫𝐞𝐞! 🧠 Forbes feature: https://www.forbes.com/sites/williamhaseltine/2025/12/29/how-our-own-cells-could-implant-the-next-generation-of-nonsurgical-brain-microchips/ 🎥 MIT Video: https://www.youtube.com/watch?v=dDcgLM6Glg4 📖 MIT news release: https://news.mit.edu/2025/new-therapeutic-brain-implants-defy-surgery-need-1105
Two Novel Strategies Supercharge Cancer Immunity
2 new ways to get the immune system revved up vs cancer —intratumor vaccination https://t.co/PUWOHy8Dkw —bacterial outer membrane vesicles https://t.co/2xC5PAC8OG
Lab Automation Accelerates: RACs Deploy in Boston
Check out the video below from Rashard showing how we test the integration of ginkgo’s RAC automation with the specific vagaries of a piece of fancy lab equipment— then mine showing a bunch of RACs showing up for our new...
Measles Cases Surge to Highest Since 1991
1. New #measles numbers out from #CDC. Confirmed cases for 2025 stand at 2,144, the highest single year count since 1991. A decision was taken in 1989 to make measles vaccination a 2-dose regimen; after it was implemented, it &...
High Lp(a) Raises Long‑Term Risk; Therapies Coming
The risk of high lipoprotein A [Lp(a)] in nearly 28,000 healthy women followed for 30 years. Fortunately, after waiting for decades, we will have drugs vs Lp(a) soon to reduce this risk https://t.co/SfXTtpaV0i https://t.co/PdykVP6nKB
Mitochondria Transfer From Glia Offers Neuropathy Therapy
Discovery of a new potential approach for treating peripheral neuropathy: mitochondria transfer from satellite glial cells to neurons @Nature https://t.co/EZxAkbi6kk https://t.co/I4td8aScPP
Atrial Fibrillation Drives Cognitive Decline, Not Prevented by Blood Thinners
Atrial fibrillation and cognitive decline. Blood thinners don't help. Possible explanations not mentioned here include less brain clearance of metabolic waste products with this heart rhythm, recently documented https://t.co/IWzR05JaBN https://t.co/5UA4vcW3GO
Elon Musk Proves Society Now Embraces Higher Tech Risk
Yeah I agree -- I think @elonmusk has shown in the last 10 years that you can take more risk than people thought in the world of atoms. (that's in part why the vibe is it like it is in...
Perturb-Seq Maps T Cell Regulators and Immune Traits
Genome-scale perturb-seq in primary human CD4+ T cells maps context-specific regulators of T cell programs and human immune traits https://t.co/tMc4efSMxe https://t.co/XUdax0qxn1
Small P-Values Aren't Always Biologically Meaningful in Bioinformatics
1/ Bioinformatics is NOT just statistics. The p-value is small, but is it biologically meaningful? Let’s talk. 🧵 https://t.co/iRgiOXPR8v
Oral MRT‑8102 Shows Rapid Biomarker Drop, Upside Remains
$GLUE +45% MRT-8102 delivers eye-catching 4-week biomarker win with clean early safety and the convenience of an oral approach. MRT-8102 degrades NEK7, a scaffolding protein essential for NLRP3 inflammasome assembly, shutting down upstream activation of IL-1β/IL-18 and downstream IL-6/hsCRP, which...
Timmerman Traverse Reaches $1M Milestone, Kilimanjaro Countdown
Timmerman Traverse for Damon Runyon Cancer Research Foundation has hit its $1M goal. One month to go before Kilimanjaro. https://t.co/xb01xFyZoG
Sequencing Depth Introduces Predictable Artifacts Affecting DE Analysis
1/ Different sequencing depths don't just change detection. They create specific, predictable artifacts that propagate into your DE calls and any downstream modeling. https://t.co/u0U7E5yq6J
Europe Pharma R&D Lags, Companies Flee to U.S.
1/🚨Here is another great article - by FT excellent global Pharma correspondent @aanuadeoye, which wonderfully describes the rapid decline of the European 🇪🇺 and British 🇬🇧 Biotech and Pharma ecosystem and the growing gap between them and the American 🇺🇸...
Project Updates: Prototype Chassis Needed, Sucrose Transformation Progress
So first thing will be to recap the progress of both projects and make a gameplan. I have a draft prototype of the 24well reader but needs chassis work to fit the plate just right, hinge, magnetic assembly, etc. Sucrose needs...
Recreate Any Bioinformatics Figure Easily with One Trick
The Secret to Recreating Any Bioinformatics Figure (It’s easier than You Think). The other day, I was on Bioinformatics subReddit and saw someone ask how to generate the figure below https://t.co/5oOU8As3T3
Pain‑free Surgery Once Seemed Impossible, Now It's Reality
If restoring youthful function in old tissues sounds radical, remember that surgery without pain once did to
